These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20923712)

  • 1. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration.
    Muresanu DF; Alvarez XA; Moessler H; Buia M; Stan A; Pintea D; Moldovan F; Popescu BO
    J Neurol Sci; 2008 Apr; 267(1-2):112-9. PubMed ID: 18048059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.
    Guekht AB; Moessler H; Novak PH; Gusev EI;
    J Stroke Cerebrovasc Dis; 2011; 20(4):310-8. PubMed ID: 20656516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial.
    Black S; Román GC; Geldmacher DS; Salloway S; Hecker J; Burns A; Perdomo C; Kumar D; Pratt R;
    Stroke; 2003 Oct; 34(10):2323-30. PubMed ID: 12970516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer's disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin.
    Alvarez XA; Cacabelos R; Sampedro C; Aleixandre M; Linares C; Granizo E; Doppler E; Moessler H
    Eur J Neurol; 2011 Jan; 18(1):59-68. PubMed ID: 20500802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.
    Alvarez XA; Sampedro C; Figueroa J; Tellado I; González A; García-Fantini M; Cacabelos R; Muresanu D; Moessler H
    J Neural Transm (Vienna); 2008 May; 115(5):683-92. PubMed ID: 18273537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrolysin for vascular dementia.
    Chen N; Yang M; Guo J; Zhou M; Zhu C; He L
    Cochrane Database Syst Rev; 2013 Jan; (1):CD008900. PubMed ID: 23440834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with Cerebrolysin.
    Molloy DW; Standish TI
    J Neural Transm Suppl; 2000; 59():293-300. PubMed ID: 10961441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.
    Gauthier S; Proaño JV; Jia J; Froelich L; Vester JC; Doppler E
    Dement Geriatr Cogn Disord; 2015; 39(5-6):332-47. PubMed ID: 25832905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer's disease patients treated with the neurotrophic agent cerebrolysin.
    Alvarez XA; Sampedro C; Cacabelos R; Linares C; Aleixandre M; García-Fantini M; Moessler H
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):867-72. PubMed ID: 19531281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine treatment of vascular dementia: a randomized trial.
    Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
    Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with using high doses of cerebrolysin in vascular dementia].
    Iakhno NN; Damulin IV; Zakharov VV; Levin OS; Elkin MN
    Ter Arkh; 1996; 68(10):65-9. PubMed ID: 9026950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-dependent effects of Cerebrolysin on EEG and short-term memory of healthy volunteers during control and hyperventilation induced cerebral ischemia.
    Funke M; Fiehler J; Mewes I; Eiselt M; Rother I; Windisch M
    J Neural Transm Suppl; 1998; 53():385-98. PubMed ID: 9700674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
    Bullock R; Erkinjuntti T; Lilienfeld S;
    Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Ruether E; Husmann R; Kinzler E; Diabl E; Klingler D; Spatt J; Ritter R; Schmidt R; Taneri Z; Winterer W; Koper D; Kasper S; Rainer M; Moessler H
    Int Clin Psychopharmacol; 2001 Sep; 16(5):253-63. PubMed ID: 11552768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.
    Panisset M; Gauthier S; Moessler H; Windisch M;
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1089-104. PubMed ID: 12111446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.